Correction, 18 September 2026: an earlier version of this post described May 7, 2026 as the end of the quarter. It is the date the results were reported.
What changed
BEAM (Beam Therapeutics) posted results for the quarter reported on May 7, 2026, and the headline number is hard to ignore: quarterly revenue grew 324.9% year over year. For a clinical-stage gene-editing company, that kind of top-line move typically reflects a licensing deal, collaboration payment, or milestone recognition rather than product sales at scale — but we don't have a breakdown in front of us.
On the bottom line, the per-share loss narrowed to -$0.91 from -$1.24 in the same period a year earlier. That is still a loss, but the direction is the right one. The company has no trailing P/E, which is expected given it is not yet profitable.
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.
We don't have guidance commentary from management to add context here.
What it means
The ACCE score for BEAM sits at 42/100. Breaking that down: Growth scores 64, Momentum 61, Quality 31, and Value 10. The Growth and Momentum readings are consistent with the revenue surge and the stock's 1-year return of +37.4%. The low Value score (10) reflects the gap between the current price of $25.88 and the underlying fundamentals — the company carries a net margin of -40.2%, an ROE of -5.8%, and a free cash flow yield of -13.7%. Earnings quality is flagged as concerning.
The analyst consensus target sits at $52.31, which is a significant premium to the current $25.88 price. That gap reflects optimism about the pipeline rather than current profitability, and it is worth treating with appropriate skepticism given the Quality score of 31 and the negative cash flow metrics.
Market cap stands at $2.63B. For a company burning cash at this rate, the revenue jump matters because it signals external validation — partnerships or milestones that bring real dollars in. Whether that momentum continues into future quarters is the key question, and one we can't answer without guidance.
For the live price and updated score, see acceinvestments.com/stocks/BEAM.
ACCE scores thousands of stocks across valuation models matched to each company, with fair value, conviction and the full thesis on every name. Start free, no card required.
